Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Chapter 1: Screening, diagnosis & staging of breast cancer and multidisciplinary team working

Breast cancer screening (continued)

In general, screening-detected BCs are associated with a favourable prognosis

Prognosis of screening-detected cancers is favourable even when compared with non-screening-detected cancers of a similar size.

Breast Cancer-Essentials-Fig1.19

Figure 1.19: Interval cancer detection.
Credit: courtesy of the authors.

Interval cancers that are detected between the screening rounds tend to have a less favourable prognosis compared with screening-detected cancers.

The benefits of BC screening need to be balanced with its potential harms. Screening is associated with a small radiation hazard. 

Breast Cancer-Essentials-Fig1.20

Figure 1.20: US-guided breast biopsy.
Abbreviations: US, ultrasound.
Credit: courtesy of the authors.

False-positive findings may lead to re-imaging and a breast biopsy. Some screening-detected ductal in situ carcinomas and small cancers (about 10%) are over-diagnosed, unlikely to threaten life, leading to overtreatment. 

Screening carries a risk for false-negative findings (about 20%), which may lead to unsubstantiated feeling of security and cancer detection as interval cancer.

Annual screening with MRI of the breast and US or mammography is recommended for women with a high familial BC risk, when risk-reducing mastectomy is not the preferred option. 

When the familial risk is high, intensified screening including MRI detects BC earlier compared with mammography screening alone.

Breast Cancer-Essentials-Fig1.21

Figure 1.21: A pedigree suggesting a high hereditary BC risk.
Abbreviations: BC, breast cancer.
Credit: courtesy of the authors.

When a germline pathogenic variant of BRCA1, BRCA2 or PALB2 is present, intensified screening should start at age 30, or 5 years younger than the age at which the youngest relative was diagnosed with BC.

Revision questions
  1. Is the prognosis of interval cancers comparable to that of screening-detected cancers?
  2. What are the potential harms associated with mammography screening?
  3. What imaging modalities should be used when familial BC risk is high?
Breast cancer screening Summary and Further Reading

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.